34.20

3.86% 1.27

After Hours: 34.20

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $34.20, with a volume of 573.47K. It is up +3.86% in the last 24 hours and up +39.53% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Previous Close:

$32.93

Open:

$32.85

24h Volume:

573.47K

Relative Volume:

1.45

Market Cap:

$1.04B

Revenue:

$339.92M

Net Income/Loss:

$-12.83M

P/E Ratio:

-79.63

EPS:

-0.4295

Net Cash Flow:

$4.52M

1W Performance:

+15.46%

1M Performance:

+39.53%

6M Performance:

+17.08%

1Y Performance:

+71.26%

1-Day Range:

$32.14

$34.70

1-Week Range:

$28.72

$34.70

52-Week Range:

$17.72

$44.28

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1080)

Industry

Diagnostics & Research (50)

Phone

866-788-9007

Address

1500 W. PARKWOOD AVE., FRIENDSWOOD, TX

Employee

942

Twitter

@castlebio

Next Earnings Date

2026-07-30

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL vs TMO, DHR, NTRA, A, IDXX

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	34.20	1.01B	339.92M	-12.83M	4.52M	-0.4295
TMO Thermo Fisher Scientific Inc	629.27	232.03B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	218.85	151.78B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	332.03	46.82B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	159.00	44.14B	7.23B	1.41B	1.09B	4.979
IDXX Idexx Laboratories Inc	556.93	43.00B	4.45B	1.10B	1.06B	13.59

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

Aug 21, 2026

238,204 Shares in Castle Biosciences, Inc. $CSTL Acquired by Advisors Capital Management LLC - MarketBeat

Aug 21, 2026

Aug 20, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 20, 2026

Aug 19, 2026

Castle Biosciences CCO Tobin W Juvenal Sells 1,730 Shares via 10b5-1 Trading Plan - Kalkine Media

Aug 19, 2026

Castle (CSTL) Results Versus Estimates: EPS Beats Its Estimate in the Current Update; After Earnings: The Stock Ends Up 5.75% for the Current SessionEarnings Season Outlook - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Castle Biosciences CFO Frank Stokes Sells 24,908 Shares in Open Market Transaction - Kalkine Media

Aug 18, 2026

Castle Biosciences (CSTL) CFO sells 24,908 company shares - Stock Titan

Aug 18, 2026

Castle Biosciences (CSTL) Edges Lower to $29.66: Diagnostic Stock Holds Key Support ZoneProfitability Factor - vinanet.vn

Aug 18, 2026

Aug 17, 2026

Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas - marketscreener.com

Aug 17, 2026

Castle Biosciences gains dual listing on Nasdaq Texas By Investing.com - Investing.com Australia

Aug 17, 2026

Castle Biosciences gains dual listing on Nasdaq Texas - Investing.com

Aug 17, 2026

Castle Biosciences Approved for Dual Listing on Nasdaq Texas - PR Newswire

Aug 17, 2026

AIGH Capital Management LLC Buys Shares of 545,101 Castle Biosciences, Inc. $CSTL - MarketBeat

Aug 17, 2026

Aug 16, 2026

Quantinno Capital Management LP Purchases 36,144 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat

Aug 16, 2026

Aug 14, 2026

Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF V - GuruFocus

Aug 14, 2026

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ - Stock Titan

Aug 14, 2026

CSTL (CSTL) insider and family trusts detail planned and recent stock sales - Stock Titan

Aug 14, 2026

Aug 13, 2026

Wasatch Advisors LP Sells 175,687 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat

Aug 13, 2026

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction - MarketBeat

Aug 13, 2026

Aug 12, 2026

Castle Biosciences at canaccord growth conference: growth broadens - Investing.com

Aug 12, 2026

Aug 11, 2026

Castle Biosciences (CSTL) Inches Higher as Shares Hold Above Key SupportIV Contraction - Vinanet

Aug 11, 2026

Aug 07, 2026